[Turnover time of tissular norepinephrine: influence of treatment with alpha-methylparatyrosine on the disappearance speed of endogenic norepinephrine and the fixation of 3 H-noradrenaline in different organs of the rat].

J. Bralet,A. Beley,A. Lallemant,A. Bralet

DOI: https://doi.org/10.1007/BF00588005

Abstract:

What problem does this paper attempt to address?

N-Acetyl and Glutamatergic Neurometabolites in Perisylvian Brain Regions of Methamphetamine Users

Jinsong Tang,Joseph O'Neill,Jeffry R. Alger,Zhiwei Shen,Maritza C. Johnson,Edythe D. London

DOI: https://doi.org/10.1093/ijnp/pyy042

2018-01-01

Abstract:Background: Methamphetamine induces neuronal N-acetyl-aspartate synthesis in preclinical studies. In a preliminary human proton magnetic resonance spectroscopic imaging investigation, we also observed that N-acetyl-aspartate+N-acetyl-aspartyl-glutamate in right inferior frontal cortex correlated with years of heavy methamphetamine abuse. In the same brain region, glutamate+glutamine is lower in methamphetamine users than in controls and is negatively correlated with depression. N-acetyl and glutamatergic neurochemistries therefore merit further investigation in methamphetamine abuse and the associated mood symptoms. Methods: Magnetic resonance spectroscopic imaging was used to measure N-acetyl-aspartate+N-acetyl-aspartylglutamate and glutamate+glutamine in bilateral inferior frontal cortex and insula, a neighboring perisylvian region affected by methamphetamine, of 45 abstinent methamphetamine-dependent and 45 healthy control participants. Regional neurometabolite levels were tested for group differences and associations with duration of heavy methamphetamine use, depressive symptoms, and state anxiety. Results: In right inferior frontal cortex, N-acetyl-aspartate+N-acetyl-aspartyl-glutamate correlated with years of heavy methamphetamine use (r = +0.45); glutamate+glutamine was lower in methamphetamine users than in controls (9.3%) and correlated negatively with depressive symptoms (r = -0.44). In left insula, N-acetyl-aspartate+N-acetyl-aspartyl-glutamate was 9.1% higher in methamphetamine users than controls. In right insula, glutamate+glutamine was 12.3% lower in methamphetamine users than controls and correlated negatively with depressive symptoms (r = -0.51) and state anxiety (r = -0.47). Conclusions: The inferior frontal cortex and insula show methamphetamine-related abnormalities, consistent with prior observations of increased cortical N-acetyl-aspartate in methamphetamine-exposed animal models and associations between cortical glutamate and mood in human methamphetamine users.
Temporal Trends in Methamphetamine Use in Patients Admitted to the Hospital: A Retrospective Cohort Study

Daniel J Suto,Jessica Xiao,Amy L Bellinghausen,Mazen Odish,Daniel A Sweeney,Gabriel Wardi,Robert L Owens,Daniel J. Suto,Amy L. Bellinghausen,Daniel A. Sweeney,Robert L. Owens

DOI: https://doi.org/10.1097/adm.0000000000001294

2024-02-29

Journal of Addiction Medicine

Abstract:Objectives Although methamphetamine use is common, the scope of methamphetamine use and outcomes for patients admitted to the hospital is unclear. This study aims to identify the prevalence of methamphetamine use from January 2012 to January 2022, coingestions, hospital course, and readmission rate of admitted patients. Methods This was a retrospective cohort study conducted on patients admitted to our center with the following inclusions: age older than 18 years, positive/“pending confirm” value for methamphetamine on urine drug screen, and/or an International Classification of Diseases , Tenth Revision , code related to stimulant use disorder as an active issue. Urine drug screen data are reported as methamphetamine +/− and polysubstance (PS) +/−. Patient demographics, admission diagnosis, and hospital course were extracted. Statistical tests used included t tests and Mann-Whitney U tests. Results A total of 19,159 encounters were included, representing 12,057 unique patients. The median (interquartile range) age was 43 (33–54) years. Of all encounters, 35.3% were methamphetamine + and PS −, and 46.3% were methamphetamine + and PS +. Hospitalizations increased from 883 in 2012 to 2532 in 2021. The median (IQR) hospital stay was 48 (48–120) hours. Of all encounters, 16.8% included an intensive care unit (ICU) admission, and the median ICU stay was 42 (21–87) hours. A total of 2988 patients (24.7%) were readmitted within the study period, and 4988 (71.5%) returned within 1 year of the previous encounter. In context of all emergency department admissions from 2013 to 2022, 13.1% had a urine drug screen + for methamphetamine. Conclusions Hospitalizations with recent methamphetamine use doubled at our institution from 2012 to 2022. In addition, 1 in 4 is readmitted (typically within 1 year), and a minority requires ICU care.

substance abuse
NEUTROPENIA ASSOCIATED WITH CHLORTHALIDONE THERAPY.

N. A. Turner,H. J. Woodliff

DOI: https://doi.org/10.5694/j.1326-5377.1964.tb134126.x

Abstract:
Psychiatric Symptoms in Individuals Who Use Ketamine Versus Methamphetamine—implications for Glutamatergic and Dopaminergic Model for Schizophrenia: a Cohort Study

Yanhui Liao,Chang Qi,Qiuxia Wu,Jinsong Tang

DOI: https://doi.org/10.1016/s0140-6736(16)31994-8

2016-01-01

Abstract:BackgroundBoth ketamine and methamphetamine have been used for studying the positive, negative, and cognitive symptoms, and dopaminergic and GABAergic dysfunction observed in acute schizophrenia. We aimed to explore and compare the prevalence and factor structure of psychotic symptoms in chronic ketamine and methamphetamine users.MethodsWe recruited chronic ketamine and methamphetamine users from the Guangzhou Baiyun and Kangda voluntary drug rehabilitation centres in the Hunan Province, China. All these participants met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for lifetime ketamine or methamphetamine dependence determined from the Structured Clinical Interview. Participants were excluded if they met criteria for other substance dependence (excluding nicotine) at any time. All participants gave a full history of psychiatric symptoms. We used The Positive and Negative Syndrome Scale (PANSS) to assess the psychotic symptoms in these two groups. Independent sample t-tests or χ2-square test were done to determine group differences. The protocol was approved by the university ethics committee (S163, 2011).FindingsWe recruited 344 chronic ketamine users (34 were female; mean age 26·8 years, SD 5·43; mean years of education 11·6 years, SD 2·45) and 456 chronic methamphetamine users (28 were female; mean age 29·3 years SD 6·33, mean years of education 11·1 years, SD 2·78) between Jan 1, 2012, to Dec 31, 2015. 183 (53%) of 344 ketamine users and 375 (82%) of 456 methamphetamine users (χ2 t=78·37, p<0·0001) had psychiatric symptoms, with a mean duration of 23·5 months (SD 24·58) for ketamine users and 15·0 months (SD 19·42) for methamphetamine users (t=4·05, p<0·0001). The mean age when first having psychotic symptoms was 25·4 years (SD 5·55) in ketamine users and 28·5 years (6·33) in methamphetamine users (t=–5·84, p<0·0001). Mean scores on PANSS TOTAL were 52·6 (SD 23·34) in ketamine users and 61·7 (29·61) in methamphetamine users (t=–4·84, p<0·0001). Mean scores for ketamine and methamphetamine use groups on positive, negative, and general subscales were 10·8 (SD 5·45) versus 15·0 (8·26; t=–8·80, p<0·0001), 12·2 (6·91) versus 14·5 (8·68; t=–4·07, p<0·0001), and 29·7 (12·98) versus 32·2 (15·22; t=–2·55, p=0·011), respectively.InterpretationThis study provides first evidence for comparing psychotic symptoms in chronic ketamine and chronic methamphetamine users. The findings suggest that chronic methamphetamine users have higher risk of suffering from psychiatric symptoms and more severity of chronic drug-induced schizophrenia-like symptoms than do chronic ketamine users. These findings might provide some implications for pharmacological (glutamatergic and dopaminergic) models of schizophrenia.FundingNatural Science Foundation of China (81100996 to YL, and 81371480 to JT). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Selective detection of 5-methylcytosine sites in DNA.

Sébastian Bareyt,T. Carell

DOI: https://doi.org/10.1002/ANIE.200702159

Angewandte Chemie

Abstract:
Impact of methamphetamine use on HIV and other health outcomes at an urban HIV medicine clinic

Laura Bamford,Amutha Rajagopal,David Grelotti,Vernay Justice-Royster,Afsana Karim,Jessica Montoya

DOI: https://doi.org/10.1097/QAD.0000000000003975

IF: 4.632

2024-11-01

AIDS

Abstract:Background: The methamphetamine epidemic threatens progress towards ending the HIV epidemic in the United States. Further characterizing the prevalence and impact of methamphetamine use among people with HIV (PWH) is necessary to inform integrated HIV and methamphetamine treatment strategies. Methods: We conducted a retrospective chart review to characterize methamphetamine use among 3092 PWH at an urban HIV Medicine clinic between July 1, 2022 and June 30, 2023. The chi-squared test was utilized to assess for statistically significant differences in demographics and HIV and other health outcomes among PWH who use and do not use methamphetamine. Results: The prevalence of methamphetamine use among PWH in this cohort was 17%. PWH who used methamphetamine were more likely to be <40 years of age, identify as White race, live in neighborhoods with low Healthy Places Index scores, identify as lesbian, gay, or bisexual, report male sex with men (MSM), MSM and injection drug use (IDU), or IDU as HIV transmission risk factor, miss scheduled HIV primary care visits, and screen positive for hepatitis C virus antibody, gonorrhea, chlamydia, and major depressive disorder. PWH who use methamphetamine were also less likely to be virally suppressed and have a CD4 + cell count ≥200 cells/mm 3 . Conclusion: Methamphetamine use is prevalent among PWH at this urban HIV Medicine Clinic and is associated with worse HIV and other health outcomes which likely increase the risk of HIV transmission. The integration of methamphetamine use disorder treatment into HIV primary care is necessary to work toward ending the syndemics of methamphetamine and HIV.
A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms

Xiangwen Chang,Yan Sun,Yang Zhang,Jiana Muhai,Lin Lu,Jie Shi

DOI: https://doi.org/10.3389/fpsyt.2018.00603

IF: 4.7

2018-01-01

Frontiers in Psychiatry

Abstract:The illegal use of methamphetamine (MA) is a growing public health concern globally and results in a series of negative effects. The prominent detrimental effect of MA use is MA-related psychiatric symptoms (MAP) and is observed at a much higher incidence compared to the general population. MAP often includes multiple dimensions of cognitive impairment and induces adverse consequences such as, violence and suicide. However, the assessment methods for MAP are not standardized. Hence, it is necessary to investigate factors that affect the progression of psychiatric symptoms in individuals who use MA. A review of published studies was performed by searching the following databases: PubMed, EMBASE, and PsycINFO from inception to 31 May, 2018. The search strategy included methamphetamine, dependence, psychiatric symptoms, and risk factor terms. We reviewed the different features of MAP and the various types of assessment instruments and summarized MAP risk factors from MA use-related factors, socio-demographic characteristics, life events, and genetic factors. We found that MAP was consistently and causally associated with MA use, particularly as it relates to the frequency and amount of MA use. Other MAP-related risk factors like life events and genetics were relatively inconsistent in their association with MAP. Hence, causal and longitudinal studies that focus on multilateral comparisons are required. This review provides high quality evidence for MAP risk factors and would be helpful for developing early prevention and treatment strategies for MAP.
Geographic and Racial/Ethnic Differences in Access to Methamphetamine Detoxification Services, United States, 2021

George Pro,Jonathan Cantor,Mance Buttram,Clare C Brown,Mofan Gu,Michael Mancino,Nickolas Zaller

DOI: https://doi.org/10.1097/MLR.0000000000002013

2024-07-01

Abstract:Introduction: Methamphetamine detoxification before entering formal and longer term treatment may have a positive impact on treatment retention and success. Understanding geographic distribution of methamphetamine specialty detox services and differential access by race/ethnicity is critical for establishing policies that ensure equitable access across populations. Methods: We used the Mental health and Addiction Treatment Tracking Repository to identify treatment facilities that offered any substance use detoxification in 2021 (N=2346) as well as the census block group in which they were located. We sourced data from the US Census Bureau to identify the percentage of a census block group that was White, Black, and Hispanic. We used logistic regression to model the availability of methamphetamine-specific detox, predicted by the percentage of a block group that was Black and Hispanic. We adjusted for relevant covariates and defined state as a random effect. We calculated model-based predicted probabilities. Results: Over half (60%) of detox facilities offered additional detox services specifically for methamphetamine. Sixteen states had <10 methamphetamine-specific detox facilities. The predicted probability of methamphetamine-specific detox availability was 60% in census block groups with 0%-9% Black residents versus only 46% in census block groups with 90%-100% Black residents, and was 61% in census block groups with 0%-9% Hispanic residents versus 30% in census block groups with 90%-100% Hispanic residents. Conclusions: During an unprecedented national methamphetamine crisis, access to a critical health care service was disproportionately lower in communities that were predominately Black and Hispanic. We orient our findings around a discussion of health disparities, residential segregation, and the upstream causes of the systematic exclusion of minoritized communities from health care.
Emergency Room Utilization and Methamphetamine Overdose Symptoms Among Syringe Services Program Participants in Washington State

Noah D. Frank,Caleb J. Banta-Green,Brandon L. Guthrie,Susan Kingston,Joe Tinsley,Lauren Whiteside,Sara N. Glick

DOI: https://doi.org/10.1080/10826084.2024.2317148

2024-02-20

Substance Use & Misuse

Abstract:Background Methamphetamine overdose can cause severe psychological and physical health issues including psychosis, heart attack, and death. People who use methamphetamine (PWUM) who experience methamphetamine overdose symptoms (MOS) are advised to seek emergency healthcare; however, factors related to seeking care are not well characterized.

psychiatry,substance abuse,psychology
Methamphetamine presentations to an emergency department: Management and complications

Katherine Z Isoardi,Sarah F Ayles,Keith Harris,Clare J Finch,Colin B Page

DOI: https://doi.org/10.1111/1742-6723.13219

2018-12-28

Emergency Medicine Australasia

Abstract:OBJECTIVE: There is little recent published data characterising methamphetamine intoxication. The present study aims to describe the clinical effects, management, complications and disposition of patients with methamphetamine exposure.METHODS: This is a retrospective review of patients presenting with methamphetamine intoxication to an ED in 2016. All presentations were extracted from a relational database and each medical record reviewed. Demographics, clinical features, complications and disposition were extracted.RESULTS: There were 378 presentations of 329 patients (234 men [71%]), median age 31 years (range 16-68 years). The most common clinical effect was acute behavioural disturbance, occurring in 295 (78%) presentations. This was successfully managed with oral sedation alone in 180 (61%) patients, with the remainder receiving parenteral sedation. Other effects included tachycardia in 212 (56%), hypertension in 160 (42%) and hyperthermia in 17 (5%) presentations. No anti-hypertensives were given. One patient was actively cooled. Complications included 21 (30%) presentations with rhabdomyolysis and 41 (13%) presentations with acute kidney injury. There were two seizures, three intracranial bleeds and one myocardial infarction. The majority (317 [84%]) of patients were managed solely within the ED. The median length of stay was 14 h. There were 41 (11%) mental health admissions. Two deaths occurred: one following an out-of-hospital cardiac arrest and the other a subarachnoid haemorrhage.CONCLUSION: The main toxicity seen with methamphetamines is acute behavioural disturbance, which is managed well with sedation. Complications, apart from rhabdomyolysis and acute kidney injury, are rare. Most patients are managed within the ED and discharged home.

emergency medicine
Methamphetamine intoxication and suicidal ideation/behavior in the emergency department

Huseyin Bayazit,Regina Baronia,Sarah M. Wakefield

DOI: https://doi.org/10.1080/03007995.2024.2333429

2024-04-06

Current Medical Research and Opinion

Abstract:Background This study investigates the association between Methamphetamine (MA) intoxication and suicidal ideation/behavior in patients presenting to emergency departments. Amidst rising MA use and co-use with opioids, this "twin epidemic" has manifested in increasing admissions for MA intoxication, often accompanied by psychiatric symptoms that can escalate to suicidal behaviors.

medicine, general & internal, research & experimental
Abstract WP165: Meth Use and Intracerebral Hemorrhage: Really "Breaking Bad"

Elizabeth Anderson,Tracie Schroeder,Michael F Waters,Daniel Gonzalez,Supreet Kaur,Lynn Ashby,Tiffany O Sheehan,Patricia Teran,David Z Wang

DOI: https://doi.org/10.1161/str.55.suppl_1.wp165

IF: 10.17

2024-02-01

Stroke

Abstract:Background: Unlike other stimulants, methamphetamine (meth) is highly addictive and can be injected, snorted, smoked, or ingested orally. Due to increased access, its use has increased globally. Recent studies have shown that there was no significant difference in hospital outcomes between ICH positive patients who utilize meth versus those who do not. However, there has not been a comprehensive evaluation of methamphetamine related ICH in recent times. Our objective is to determine if meth use impacts ICU length of stay/need for sedating agents, and if meth use varies by ethnicity in the ICH population. Methods: This is an IRB approved retrospective review of all patients with acute ICH at a large academic stroke center from 2017 to 2023. Data collected and analyzed include demographics, ICH score/size, intraventricular hemorrhage, location of hematoma, surgical intervention, GCS/NIHSS scores, ICU length of stay (LOS), and discharge destiny. Statistics used include Pearson’s Chi-squared test and Wilcoxon rank sum test. Results: Of 70 ICH patients with all data elements, 32 (46%) were meth users, with an average age of meth positive patients at 59. In our Hispanic population, significant meth use was seen (41% v 13%, p = 0.009). ICH patients had significant NICU LOS (10.1 v 6.1 days, p < 0.001), with longer hospital mean LOS (12.4 v 7.8 days, p = 0.007). They also required more sedatives (63% v 37%, p = 0.032). Meth use was not associated with larger ICH size (15.7 v 29.2, p = 0.406), but was associated with higher discharge mRS (4.7 v 4.3, p = 0.788). Conclusions: Our study demonstrates that in ICH positive patients, meth-use was associated with increased use of sedatives and increased length of stay, as well as higher discharge mRS. However, it was not associated with larger ICH size. Hispanic ethnicity and ICH also appear to have a relationship, although that relationship needs to be further elucidated. Discussion: Methamphetamine is easily and relatively inexpensive to make, with over-the-counter ingredients such as pseudoephedrine. With over 35 million people using meth worldwide, our data found that the average user was older than previously thought. As ICH is one of the major complications of meth use, ICH has a major impact on complexity of care and health economics.

peripheral vascular disease,clinical neurology
A note on homogeneous complex contact manifolds

W. Boothby

DOI: https://doi.org/10.1090/S0002-9939-1962-0137126-2

1962-02-01

Abstract:
Changes in activities of uridine diphosphate-glucuronyltransferases during chemical hepatocarcinogenesis.

Z. Yin,K. Sato,H. Tsuda,N. Ito

1982-04-01

Abstract:Changes in the activities of hepatic uridine diphosphate-glucuronyltransferases (UDP-GTs) were investigated during the induction of hyperplastic nodules (enzyme-altered foci) by a system consisting of diethylnitrosamine (DEN) followed by N-2-fluoroenylacetamide (FAA) and including partial hepatectomy. The activity of the late fetal form of UDP-GT, which was assayed towards o-aminophenol (o-GT activity), was induced rapidly by a single ip injection of DEN (200 mg/kg) or 3-methylcholanthrene (40 mg/kg) or by the continuous administration of FAA (0.02% in diet) alone. This activity further increased with the appearance of the nodules, while the activity of the neonatal form, which was assayed toward phenolphthalein (p-GT activity) and was inducible by phenobarbital, increased only slightly. The increased o-GT activity showed a good correlation with the increased number or area of enzyme-altered foci detected by gamma-glutamyltransferase activity staining, but the p-GT activity did not, though it was significantly increased. In hyperplastic nodules and well differentiated hepatomas induced by DEN (0.1% in drinking water, 3 weeks) but isolated long after cessation of DEN, o-GT activity was markedly increased, but p-GT activity was decreased or remained at the level of normal rat liver. These data indicate that the increased o-GT activity may be one of the enzyme markers for preneoplastic hepatic cells. An antioxidant, butylated hydroxyanisole (BHA) (0.75% in diet), markedly elevated the hepatic o-GT activity rapidly after being administered with FAA in the above system, and the induction of the nodules was inhibited.
National trends in drug overdose mortality in Asian American, Native Hawaiian, and Pacific Islander populations, 2018-2022

David T. Zhu,Andrew Park

DOI: https://doi.org/10.1101/2024.09.17.24313831

2024-09-18

Abstract:ABSTRACT Background Drug overdose deaths have surged over the past two decades, disproportionately impacting racial/ethnic minority populations. Yet, little is known about drug overdose patterns among Asian American and Native Hawaiian/Pacific Islander (AANHPI) populations. Methods We obtained data on drug overdose deaths and population totals from the CDC WONDER Multiple Cause of Death database and American Community Survey between 2018 and 2022. We calculated crude mortality rates per 100,000, stratified by sex, US Census Division, and drug types: prescription opioids, heroin, fentanyl, cocaine, methamphetamine, and benzodiazepines. Additionally, we conducted disaggregated analyses for six Asian American subgroups (Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese) and three NHPI subgroups (Hawaiian, Guamanian, Samoan). Results In 2022, there were 1226 drug overdose deaths among Asian Americans and 154 among NHPI individuals. The crude mortality rate for NHPI individuals (17.52 per 100,000; 95% CI: 14.76-20.29) tripled that of Asian Americans (5.85 per 100,000; 95% CI: 5.52-6.18). Fentanyl was the leading cause of overdose deaths among Asian Americans (3.17 per 100,000; 95% CI: 2.93-3.41), whereas methamphetamine was predominant among NHPI individuals (11.38 per 100,000; 95% CI: 9.15-13.61). Among Asian American subgroups, Japanese Americans had the highest mortality rate (9.90 per 100,000; 95% CI: 9.61-10.2), and among NHPI subgroups, Guamanians had the highest rates (43.16 per 100,000; 95% CI: 39.05-48.24). Conclusions These findings underscore the urgent need for culturally competent harm reduction services, mental health and addiction treatment, and social services, addressing structural barriers that perpetuate drug overdose disparities in AANHPI communities. Keywords Drug Overdose; Asian American; Native Hawaiian; Pacific Islander; Disaggregated; Racial Disparities

Addiction Medicine
Effects of Methamphetamine and Narcotics on Sexual High-Risk Behaviors

Farah Lotfi Kashani,Shahram Vaziri,Arash Vaziri

DOI: https://doi.org/10.5812/ijhrba-127007

2022-09-08

International Journal of High Risk Behaviors and Addiction

Abstract:Background: Methamphetamine is a highly addictive psychostimulant. Narcotics also reduce anxiety and aggression and create a kind of euphoria. These characteristics provide a special attraction for the abuse of these substances for sexual behaviors, and by that, high-risk sexual behaviors. Objectives: The current research intended to compare the impact of methamphetamine and narcotics on sexual high-risk behaviors. Patients and Methods: This comparative study was performed on 91 men (49 amphetamine abusers and 42 narcotics abusers) from the patients of Yareegar Clinic in Tehran, Iran, within 2019 - 2021. A substance-influenced sexual behavior questionnaire was used to collect the data. Data were analyzed using the analysis of variance. Results: The results showed that the use of amphetamine and narcotics was significantly effective in sexual desire, function, and sexual pleasure (P < 0.001). The investigation of behaviors in the two groups showed significant differences between the two groups in increasing sexual desire, sexual pleasure, desire for sex in anonymous situations, and intimacy and eroticism in a relationship and reducing the negative emotional consequences of sexual behavior (P < 0.001). Conclusions: The use of amphetamines can provide a vicious cycle of arousal-desire by desire and intensification of sexual behaviors, thereby increasing the likelihood of the occurrence and spread of infectious disorders, a phenomenon that is also observed in the use of narcotics. By training sexual skills and making individuals more efficient and cognitive, they can be prevented from entering the aforementioned cycle.
Profile of Psychiatric Symptoms in Methamphetamine Users in China: Greater Risk of Psychiatric Symptoms with a Longer Duration of Use.

Jun Ma,Xin-Jun Sun,Ru-Jia Wang,Tong-Yu Wang,Meng-Fan Su,Mo-Xuan Liu,Su-Xia Li,Ying Han,Shi-Qiu Meng,Ping Wu,Jie Shi,Yan-Ping Bao,Lin Lu

DOI: https://doi.org/10.1016/j.psychres.2018.02.017

IF: 11.3

2018-01-01

Psychiatry Research

Abstract:Chronic methamphetamine (MA) use is associated with psychiatric symptoms. This study explored pattern of co-occurring psychiatric symptoms in MA users and their relationship to duration of MA use. A cross-sectional study was conducted among MA users at the Shenzhen Compulsory Drug Detoxification Center from April 2012 to October 2015. The Positive and Negative Syndrome Scale, Hamilton Anxiety Scale, and Beck Depression Inventory were used to assess psychiatric symptoms. Among 1277 MA users, 57.6% participants had any type of psychiatric symptoms including depressive, anxiety and psychotic symptoms. A dose-response relationship was found between duration of MA use and risk of psychiatric symptoms. The odds ratios (OR) of depressive symptoms increased with the duration of MA use (1-5 years vs. < 1 year: 1.74 [95% CI, 1.24-2.42]; ≥ 5 years vs. < 1 year: 2.07 [1.19-3.61]), so did the ORs of co-occurring anxiety and depressive symptoms (1-5 years: 1.74 [1.20-2.51]; ≥ 5 years: 3.09 [1.76-5.40]). Methamphetamine-dependent individuals were four-times more likely to experience any type of psychiatric symptoms than non-dependent users. The prevalence of psychiatric symptoms was high in chronic MA users and increased with MA use duration. Early prevention and treatment strategies targeting both MA use and associated psychiatric symptoms are needed.
Safety, risk, and aggression: Health professionals’ experiences of caring for people affected by methamphetamine when presenting for emergency care

Kim Usher,Debra Jackson,Cindy Woods,Jan Sayers,Rachel Kornhaber,Michelle Cleary

DOI: https://doi.org/10.1111/inm.12345

IF: 5.1

2017-09-27

International Journal of Mental Health Nursing

Abstract:The crystalline form of methamphetamine, commonly known as crystal meth (crystal methamphetamine) or ICE, is a highly-addictive and powerful stimulant. Users of crystal meth often require emergency care, and are associated with a substantial burden of care by emergency care providers. The aim of the present qualitative study was to explore health professionals' experiences of providing care for patients affected by ICE who presented to the emergency department (ED). Nine semistructured interviews were conducted. The major theme, 'staying safe', was revealed, in which participants described their experiences of being exposed to potentially unsafe situations, and their responses to challenging behaviours, including aggression. The findings highlight the need for ED staff to understand the nature of ICE use and its adverse impact on the mental and physical health of users. Furthermore, it is clear that establishing and maintaining safety in the emergency care setting is of utmost importance, and should be a priority for health-care managers.

nursing,psychiatry
Abstract WP125: Methamphetamine Associated Psychosis In Acute Stroke

Alan H Yee,Rikki Samuel,Guillermo Palchik

DOI: https://doi.org/10.1161/str.53.suppl_1.wp125

IF: 10.17

2022-02-01

Stroke

Abstract:Introduction: Methamphetamine, an addictive stimulant, may lead to psychosis of which little is known about the impact in acute stroke. Despite its short half-life, we hypothesize that methamphetamine use in acute stroke is associated with the development of psychosis and extends hospital length of stay (LOS). Methods: Single-center retrospective analysis (2016-2019) of consecutive adult patients admitted for acute ischemic stroke, intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (SAH), and transient ischemic attack (TIA) with methamphetamine detected on urine drug screen and were compared to those who did not. Psychosis was defined as disturbed thoughts or perceptions with abnormal psychomotor behavior. Psychosis onset and duration, clinical characteristics, total hospitalization time and intensive care unit (ICU) LOS, as well as psychotic treatment interventions were documented. Results: 138 patients were admitted for acute cerebrovascular events (87 ischemic strokes, 40ICH, 7 SAH, 2 TIAs). 69 patients tested positive for methamphetamine (68% male; mean age 53(range 26-68)) and were compared to 69 who did not (65% male, mean age 64 (range 30-93).Despite no differences in having any psychiatric illness history, 25% (17/69) of methamphetamine users experienced psychosis compared to only 3% (2/69) who did not test positive (p <0.0002). Although there was no statistical difference in hospital LOS (3.6 days in methamphetamine positive versus 2.9 days ( p =.113)), substance use abusers had significantly longer ICU stays (48 hours versus 24 hours; p =.006). NIHSS and ICH Scores were not statistically different between those who tested positive or negative for methamphetamine. Conclusions: Methamphetamine use is strongly associated with developing psychosis and when present, leads to longer ICU stay.

peripheral vascular disease,clinical neurology
Methamphetamine Use: A Narrative Review of Adverse Effects and Related Toxicities

Amber N Edinoff,Sarah E Kaufman,Keionne M Green,Daniel A Provenzano,Jesse Lawson,Elyse M Cornett,Kevin S Murnane,Adam M Kaye,Alan D Kaye

DOI: https://doi.org/10.52965/001c.38161

2022-09-15

Abstract:Methamphetamine has been labeled "America's most dangerous drug" and has received significant public health attention. Stimulant addiction and tolerance are heavily documented in the literature; increasingly larger doses maintain euphoria in short time periods to withstand stimulant tolerance. Stimulant deaths are high in the United States and abroad. Between 2013 and 2019, deaths related to methamphetamine use quadrupled from 3,616 to 16,127. Methamphetamine use increased four-fold from 2015 to 2016. Due to this increase in methamphetamine use and its associated medical complications, the mortality rate associated with methamphetamine use has doubled over the past ten years. Cardiopulmonary symptoms include chest pain, palpitations, and shortness of breath. Methamphetamine-related myocardial infarction can also occur. Central nervous system symptoms include agitation, anxiety, delusions, hallucinations, and seizures. Methamphetamine-induced psychosis may unmask underlying psychiatric disorders. It can also cause cerebral vasculitis, which elicits cortical blindness and ischemic strokes. Methamphetamine-induced neurotoxicity in serotonergic systems is more diffuse, involving the striatum, hippocampus, septum, amygdala, and hypothalamus leading to mood changes, psychosis, and memory impairment. This narrative review will aim to highlight the adverse effects as well as the toxicity that can occur with methamphetamine use.

[Turnover time of tissular norepinephrine: influence of treatment with alpha-methylparatyrosine on the disappearance speed of endogenic norepinephrine and the fixation of 3 H-noradrenaline in different organs of the rat].

N-Acetyl and Glutamatergic Neurometabolites in Perisylvian Brain Regions of Methamphetamine Users

Temporal Trends in Methamphetamine Use in Patients Admitted to the Hospital: A Retrospective Cohort Study

NEUTROPENIA ASSOCIATED WITH CHLORTHALIDONE THERAPY.

Psychiatric Symptoms in Individuals Who Use Ketamine Versus Methamphetamine—implications for Glutamatergic and Dopaminergic Model for Schizophrenia: a Cohort Study

Selective detection of 5-methylcytosine sites in DNA.

Impact of methamphetamine use on HIV and other health outcomes at an urban HIV medicine clinic

A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms

Geographic and Racial/Ethnic Differences in Access to Methamphetamine Detoxification Services, United States, 2021

Emergency Room Utilization and Methamphetamine Overdose Symptoms Among Syringe Services Program Participants in Washington State

Methamphetamine presentations to an emergency department: Management and complications

Methamphetamine intoxication and suicidal ideation/behavior in the emergency department

Abstract WP165: Meth Use and Intracerebral Hemorrhage: Really "Breaking Bad"

A note on homogeneous complex contact manifolds

Changes in activities of uridine diphosphate-glucuronyltransferases during chemical hepatocarcinogenesis.

National trends in drug overdose mortality in Asian American, Native Hawaiian, and Pacific Islander populations, 2018-2022

Effects of Methamphetamine and Narcotics on Sexual High-Risk Behaviors

Profile of Psychiatric Symptoms in Methamphetamine Users in China: Greater Risk of Psychiatric Symptoms with a Longer Duration of Use.

Safety, risk, and aggression: Health professionals’ experiences of caring for people affected by methamphetamine when presenting for emergency care

Abstract WP125: Methamphetamine Associated Psychosis In Acute Stroke

Methamphetamine Use: A Narrative Review of Adverse Effects and Related Toxicities